Skip to content

Study · Animal study (in vivo) · rat · 2010

9 results

Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke.

Zhang C, Chopp M, Cui Y, Wang L, Zhang R, Zhang L, Lu M, Szalad A, Doppler E, Hitzl M, Zhang ZG

Journal of neuroscience research1 Nov 2010Cited by 126 (Europe PMC)

PMID20857512 (opens in a new tab)PMCIDPMC3073377 (opens in a new tab)DOI10.1002/jnr.22495 (opens in a new tab)PepBankPUB-20857512
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats after stroke, Cerebrolysin initiated 24 hr later significantly increased BrdU-positive SVZ neural progenitor cells at 28 days.

    In plain wordsIn rats after stroke, Cerebrolysin increased BrdU-positive neural progenitor cells.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseBrdU-positive SVZ progenitor cells
    Study

    ratn: not reported in source

    Embolic middle cerebral artery occlusion
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    2.5 and 5 ml/kgAs given in this study (rat).

    Source sentences

    Summary
    Treatment with Cerebrolysin at doses of 2.5 and 5 ml/kg significantly increased the number of bromodeoxyuridine-positive (BrdU(+)) subventricular zone (SVZ) neural progenitor cells
    2 context sentences
    Summary · context
    in the ipsilateral SVZ and striatal ischemic boundary 28 days after stroke when the treatment was initiated 24 hr after stroke.
    Summary · context
    The present study investigated the effect of Cerebrolysin on neurogenesis in a rat model of embolic middle cerebral artery occlusion (MCAo).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats after stroke, Cerebrolysin initiated 24 hr later significantly increased DCX immunoreactivity in the ipsilateral SVZ and striatal ischemic boundary at 28 days.

    In plain wordsIn rats after stroke, Cerebrolysin increased DCX immunoreactivity in the SVZ and striatal ischemic boundary.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseDCX immunoreactivity
    Study

    ratn: not reported in source

    Embolic middle cerebral artery occlusion
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    2.5 and 5 ml/kgAs given in this study (rat).

    Source sentences

    Summary
    and doublecortin (DCX) immunoreactivity (migrating neuroblasts) in the ipsilateral SVZ and striatal ischemic boundary 28 days after stroke when the treatment was initiated 24 hr after stroke.
    2 context sentences
    Summary · context
    Treatment with Cerebrolysin at doses of 2.5 and 5 ml/kg significantly increased
    Summary · context
    The present study investigated the effect of Cerebrolysin on neurogenesis in a rat model of embolic middle cerebral artery occlusion (MCAo).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats after stroke, Cerebrolysin reduced TUNEL-positive cells by approximately 50% in the ischemic boundary.

    In plain wordsIn rats after stroke, Cerebrolysin reduced TUNEL-positive cells in the ischemic boundary.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseTUNEL-positive cells
    Study

    ratn: not reported in source

    Embolic middle cerebral artery occlusion
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    2.5 and 5 ml/kgAs given in this study (rat).

    Source sentences

    Summary
    The treatment also reduced TUNEL(+) cells by ∼50% in the ischemic boundary.
    2 context sentences
    Summary · context
    Treatment with Cerebrolysin at doses of 2.5 and 5 ml/kg significantly increased
    Summary · context
    The present study investigated the effect of Cerebrolysin on neurogenesis in a rat model of embolic middle cerebral artery occlusion (MCAo).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats after stroke, Cerebrolysin initiated at 24 and 48 hr did not significantly reduce infarct volume.

    In plain wordsIn rats after stroke, Cerebrolysin initiated at 24 and 48 hr did not significantly reduce infarct volume.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeInfarct volume
    Study

    ratn: not reported in source

    Embolic middle cerebral artery occlusion
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    2.5 ml/kgAs given in this study (rat).

    Source sentences

    Summary
    However, treatment with Cerebrolysin at a dose of 2.5 ml/kg initiated at 24 and 48 hr did not significantly reduce infarct volume
    1 context sentence
    Summary · context
    The present study investigated the effect of Cerebrolysin on neurogenesis in a rat model of embolic middle cerebral artery occlusion (MCAo).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats after stroke, Cerebrolysin initiated at 24 and 48 hr substantially improved neurological behavioral outcomes at 21 and 28 days.

    In plain wordsIn rats after stroke, Cerebrolysin initiated at 24 and 48 hr improved neurological behavioral outcomes at 21 and 28 days.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseNeurological behavioral outcomes
    Study

    ratn: not reported in source

    Embolic middle cerebral artery occlusion
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    2.5 ml/kgAs given in this study (rat).

    Source sentences

    Summary
    However, treatment with Cerebrolysin at a dose of 2.5 ml/kg initiated at 24 and 48 hr did not significantly reduce infarct volume but substantially improved neurological outcomes measured by an array of behavioral tests 21 and 28 days after stroke.
    1 context sentence
    Summary · context
    The present study investigated the effect of Cerebrolysin on neurogenesis in a rat model of embolic middle cerebral artery occlusion (MCAo).
  6. 06LabIn vitro (cells)Efficacy outcome

    In SVZ neural progenitor cells from ischemic rats, Cerebrolysin dose-dependently increased BrdU-positive cells.

    In plain wordsIn cells from ischemic rats, Cerebrolysin increased BrdU-positive neural progenitor cells as the dose increased.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseBrdU-positive progenitor cells in vitro
    Study

    ratn: not reported in source

    SVZ neural progenitor cells from ischemic rats
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Incubation of SVZ neural progenitor cells from ischemic rats with Cerebrolysin dose dependently augmented BrdU(+) cells and increased the number of Tuj1(+) cells (a marker of immature neurons).
  7. 07LabIn vitro (cells)Efficacy outcome

    In SVZ neural progenitor cells from ischemic rats, Cerebrolysin increased Tuj1-positive cells, a marker of immature neurons.

    In plain wordsIn cells from ischemic rats, Cerebrolysin increased Tuj1-positive cells, a marker of immature neurons.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseTuj1-positive cells
    Study

    ratn: not reported in source

    SVZ neural progenitor cells from ischemic rats
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Incubation of SVZ neural progenitor cells from ischemic rats with Cerebrolysin dose dependently augmented BrdU(+) cells and increased the number of Tuj1(+) cells (a marker of immature neurons).
  8. 08LabIn vitro (cells)Efficacy outcome

    In neural progenitor cells from ischemic rats, Cerebrolysin promoted migration.

    In plain wordsIn cells from ischemic rats, Cerebrolysin promoted neural progenitor cell migration.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseNeural progenitor cell migration
    Study

    ratn: not reported in source

    SVZ neural progenitor cells from ischemic rats
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, Cerebrolysin treatment promoted neural progenitor cell migration.
    1 context sentence
    Summary · context
    Incubation of SVZ neural progenitor cells from ischemic rats with Cerebrolysin dose dependently augmented BrdU(+) cells and increased the number of Tuj1(+) cells (a marker of immature neurons).

Studies that did not test the peptide alone1

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 09LabNot a test of Cerebrolysin aloneIn vitro (cells)Mechanism

    In SVZ neural progenitor cells from ischemic rats, PI3K/Akt pathway blockade abolished the Cerebrolysin-induced increase in BrdU-positive cells.

    In plain wordsIn cells from ischemic rats, PI3K/Akt pathway blockade abolished the Cerebrolysin-induced increase in BrdU-positive cells.

    Peptide
    Cerebrolysin
    Outcome
    DecreasePI3K/Akt blockade of BrdU-positive cell increase
    Study

    ratn: not reported in source

    SVZ neural progenitor cells from ischemic rats
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Blockage of the PI3K/Akt pathway abolished Cerebrolysin-increased BrdU(+) cells.
    1 context sentence
    Summary · context
    Incubation of SVZ neural progenitor cells from ischemic rats with Cerebrolysin dose dependently augmented BrdU(+) cells and increased the number of Tuj1(+) cells (a marker of immature neurons).

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.